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Abstract
Background: The relevance of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC) is
largely unknown. Clinical trials targeting ER with selective estrogen receptor modulators in pancreatic cancer did
not show any benefit. Here, we analyze the impact of recently characterized ER isoform beta on survival in a cohort
of patients with resected PDAC.
Methods: Eighty-four patients having undergone pancreatic resection for PDAC at a single institution were
identified. Tissue microarrays were constructed of archival tumor specimens. The expression of ER beta was
determined by immunohistochemistry and quantified by a system established for estrogen receptor expression in
breast cancer. ER beta expression was then correlated with clinicopathological parameters, and univariate and
multivariate survival analyses were performed.
Results: Nuclear expression of ER beta was found in 31% of tumors. No significant correlation was found between ER
beta expression and TNM status, tumor grade, age or sex. Univariate analysis revealed nodal metastasis and the
expression of ER beta as factors correlating with a shorter overall survival and disease free survival. When comparing ER
beta expression in patients surviving more than 24 months with those who died from the tumor within 12 or
24 months, respectively, a significantly lower ER beta expression was found in the long term survivors. In multivariate
analysis, ER beta expression was demonstrated to be an independent predictor of shorter overall survival.
Conclusions: In resected PDAC, expression of ER beta seems to correlate with poor prognosis. These data may help to
identify patients who may benefit from additional systemic therapy including selective estrogen receptor modulators.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is among the
leading causes of cancer-related mortality in western
countries [1]. In the last decade, overall survival im-
proved only marginally. To date, standard therapeutic
regimens consist of surgery, cytotoxic chemotherapy,
irradiation, or a combination [2, 3] and result in an over-
all 5 year survival of less than 10 %. More recently,
newer agents targeted against molecular determinants of
cancer cells or tumor vessels, or both, have been tested
in clinical trials to expand the therapeutic armamentar-
ium [4, 5]. When characterizing molecular targets for
potential prognostic and therapeutic use, differences in
the sex distribution have led to the investigation of the
role of estrogen receptors (ER) in the development and
progression of pancreatic cancer and other malignancies
[6–11]. Most early trials with the selective estrogen re-
ceptor modulator tamoxifen in PDAC yielded only a
moderate survival benefit while showing an acceptable
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safety profile [12–14]. This concept of inhibition of ER
mediated effects however did not take into account re-
cently reported existence of differential signaling of ER
isoforms ERα and ERβ [15–17].
Human ERβ was cloned in 1996 for the first time and
subsequently was shown to have a ligand binding specifi-
city and a signaling response to estrogen agonists that is
distinct from ERα [15–18]. While ERα was demon-
strated to promote tumor growth and angiogenesis in
breast cancer and many other solid tumor types, the role
of ERβ is defined much less clearly.
In ERα negative breast cancer specimens, ERβ was
shown to correlate with a higher proliferation index [9].
Furthermore, in breast cancer patients, ERβ was charac-
terized as a response marker of the selective estrogen re-
ceptor modulator tamoxifen in unselected cohorts and in
patients negative for ERα [19, 20]. In non small cell lung
cancer patients results are controversial. While in one
study, high ERβ expression served as a negative prognostic
marker and correlated with a worse outcome [21], a
metaanalysis failed to find a consistent correlation of ERβ
expression with survival [22]. Beside ERβ-specific effects,
ERβ activation seems to interfere with EGF receptor sig-
naling via an activation of the MAP kinase [10, 23].
While pancreatic cancer cell lines were reported to ex-
press ERβ [24], there is no consistent information available
on the expression of ERβ in human pancreatic ductal
adenocarcinoma specimens and its correlation with histo-
pathological parameters and prognostic consequences [8].
The present study was designed to analyze the influence
of ERβ expression on overall and disease free survival in
PDAC. Here, in a cohort of 94 patients having undergone
a pancreatic resection, we correlate ERβ expression in a
tissue microarray derived from intraoperative tumor spec-
imens with clinicopathological and survival parameters.
Methods
Patients
We identified 111 consecutive patients from a prospect-
ive database of patients operated for ductal pancreatic
adenocarcinoma at a single institution. Of these, clinico-
pathological information and prospectively collected fol-
low up data as well as archived tumor material were
available for evaluation in 84 patients. Patients with dis-
tant metastases were excluded from the study as well as
patients who died within 30 days after resection. Specif-
ically, information on age, sex, date of the primary sur-
gery, perioperative irradiation or chemotherapy, TNM
tumor status and grading, date last seen, date of death,
cause of death, and date of the first identification of
tumor progression were extracted from the original pa-
tient charts and a regional tumor registry database. The
study was approved by the Ethics Committee of the
Hospital of the University of Munich. Due to the
retrospective nature of the study, explicit consent was
not required.
Tissue microarray construction
Paraffin embedded archive tissue material of tumor and
surrounding normal pancreatic tissue was used to gener-
ate tissue microarrays (TMAs) after confirming the
histological diagnosis of PDAC by a pathologist blinded
for the clinical data.
TMAs were prepared essentially as published before
[25]. In brief, the area of interest to be sampled was identi-
fied and marked on an areal slide corresponding to each
paraffin block. Three tissue core biopsies, each 0.6 mm in
diameter, were punched out of the donor paraffin block
and then arrayed in each of the respective recipient TMA
blocks using a manual arrayer (Beecher Instruments, Sun
Prairie, WI). Edge confusion was ensured by incubating
the TMAs at 37 °C for 30 min. Sections of 2 μm thickness
were cut onto adhesive glass slides (Super Frost Plus,
Menzel, Braunschweig, Germany).
Immunohistochemistry
Immunohistochemistry for ERβ was performed using
standard technique. Briefly, after deparaffinization and
rehydration, slides were blocked with bovine serum
albumin. The primary antibody (Rabbit polyclonal to
estrogen receptor beta, Abcam, Cambridge, UK), was
added in a dilution of 1:200 and incubated overnight at
4 °C. After blocking endogenous peroxidase with 7.5%
hydrogen peroxide, a horseradish-peroxidase conjugated
polyclonal goat anti-rabbit secondary antibody (Dako,
Hamburg, Germany) was added and incubated for
30 min at room temperature. Slides were counterstained
with hematoxylin.
Histopathological evaluation
ERβ expression was quantified analogous to the scoring
system proposed by Remmele and Stegner used for ERα
in breast cancer [26]. Briefly, staining intensity was
scored from 0 (no reaction) to 3 (strong reaction), and
the percentage of stained nuclei was scored from 0 (no
positive nuclei) to 4 (more than 80% positive nuclei).
The scores of staining intensity and stained nuclei were
multiplied, yielding a total core of 0 to 12. Positive ex-
pression of ERβ was defined as a score of 3 or more.
Scoring was performed by two independent pathologists
blinded for the clinical data.
Statistical analysis
Statistical analyses were performed by utilizing IBM
SPSS statistics 23 software package (IBM, Armonk, NY).
Chi-square tests were applied to test correlation between
categorical variables. Survival curves were calculated accord-
ing to Kaplan-Meier, with differences in survival between
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strata of low and high ERβ expression and clinicopathologi-
cal parameters detected by the log-rank test. Multivariate
analysis was performed using the Cox proportional hazards
model including variables with a p value of less than 0.15 in
univariate analyses. A p value of less than 0.05 was consid-
ered statistically significant.
Results
Demographic data
The study cohort consisted of 84 patients, 41 men and
43 women with a median age of 65.6 years at the time of
the operation (range 32–82 years). Demographic and
clinicopathological characteristics of the patients are
summarized in Table 1. At the time of the analysis, 63
patients (75.0%) had died from the tumor, and three
more patients had tumor progression.
Expression of ERβ
A nuclear expression of the ERβ was detected in 26 PDAC
tumor specimens (31.0%). Representative slides are shown
in Fig. 1. No correlation was seen between ER expression
and other clinicopathological parameters, such as sex, age,
T and N stage, and histological grading. Furthermore, add-
itional therapy (chemotherapy or chemoradiation) and ER
expression did not correlate (Table 2). Interestingly, in ad-
jacent normal pancreatic tissue, ER beta expression was
detected in 41 patients (48.8%). A downregulation of ER
beta expression in tumor tissue, compared to normal tis-
sue, as defined by a lower staining score, was seen in 42
cases (50.0%).
Univariate survival analysis
Mean overall survival of all patients after resection of
the primary tumor was 27.0 months (95% confidence
interval 22.3–31.6 months), and mean disease free
survival was 21.2 months (95% confidence interval 17.2–
25.1 months). Patients with ERβ expressing tumors sur-
vived 16.6 months compared to 30.9 months in patients
without ERβ expression (p = 0.009, Fig. 2a). Disease free
survival was 13.5 months in patients with ERβ expres-
sion compared to 23.5 months in patients with no ERβ
expression (p = 0.037, Fig. 2b). Overall survival in nodal
positive patients was 21.5 months versus 33.1 months in
nodal negative patients (p = 0.021, Fig. 2a). Disease free
survival was 18.5 months in nodal positive patients
which was significantly shorter compared to 25.1 months
in patients with negative nodal status (p = 0.066, Fig. 2b).
Details are given in Table 3 and Table 4. In long term
survivors (overall survival 24 months and more, n = 25)
ERβ expression was detected in 25%, while patients who
survived less than 12 months (n = 25) showed ERβ ex-
pression in 44% (Fig. 3, p = 0.0027).
Multivariate survival analysis
To validate ERβ expression as an independent prognos-
tic indicator in PDAC on overall survival, multivariate
regression analysis was performed. Expression of ERβ
was demonstrated to be an independent prognostic indi-
cator of overall survival (hazard ratio 1.938, p = 0.047).
Of the remaining variables tested only positive nodal sta-
tus showed a trend towards adverse survival however
did not become statistically significant (hazard ratio
1.831, p = 0.069). Male sex and residual tumor status also
failed to show statistical significance in the multivariate
survival analysis. Details are shown in Table 5.
Discussion
In the present study, ERβ was expressed on PDAC in
31% of all patients. Expression of ERβ did not correlate
with any of the clinicopathological parameters examined,
however ERβ expression was strongly associated with an
adverse overall survival and disease free survival in uni-
variate analyses. Multivariate analysis showed that ERβ
expression on tumor cells was an independent prognos-
tic factors of overall survival.
Table 1 Clinicopathological parameters of 84 patients with
resected pancreatic ductal adenocarcinoma
Variable n %
Sex female 43 51.2
male 41 48.8
Age ≤60 years 24 28.6
> 60 years 60 71.4
Type of operation PD 35 41.7
PPPD 34 40.5
Distal pancreatectomy 10 11.9
TP 5 6.0
T status T1 1 1.2
T2 10 11.9
T3 68 81.0
T4 5 6.0
N status N0 35 41.7
N1 49 58.3
Residual tumora R0 39 48.1
R1 42 51.9
Histological grading G1 2 2.4
G2 28 33.3
G3 54 64.3
Perioperative therapy Chemotherapy 5 6.0
Chemoradiation 49 58.3
none 30 35.7
PD partial pancreatoduodenectomy (Kausch-Whipple procedure), PPPD pylorus
preserving partial pancreatoduodenectomy (Traverso-Longmire procedure), DP
distal pancreatectomy, TP total pancreatectomy
amissing information on resection status in three patients
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To our knowledge, this study is the largest series on ex-
pression of ER on pancreatic neoplasms. The fact that ERα
is not detectable with immunohistochemical methods on
PDAC tissue is concordant with several other smaller
studies [27, 28]. However, there are two studies which
showed ERα expression on mRNA level on PDAC [29, 30].
Whether this finding reflects ERα protein levels being
expressed in very small amounts not detectable with
immunohistochemical methods, or a missing translation of
ERα mRNA in PDAC is unknown. Interestingly, mucinous
cystic tumors seem to express ERα more frequently than
PDAC, possibly reflecting the “ovarian-type stroma” defin-
ing mucinous cystic tumors [31, 32]. Data on ERα expres-
sion in this entity is still pending.
ERβ was however expressed in nontumorous tissue,
and to a lesser extent in the corresponding PDAC speci-
mens. Compared to normal pancreatic tissue, an overall
loss of ERβ expression in PDAC was detected in the ma-
jority of the investigated cases, suggesting ERβ loss as a
molecular event in the line of tumor progression. Yet,
the presence of ERβ expression in the tumor correlates
with an adverse prognosis. This phenomenon may be ex-
plained by a crosstalk of ERβ signal transduction and
other pathways that are activated during of tumor pro-
gression, leading to a more aggressive tumor phenotype
in those subjects with an unchanged ERβ signaling path-
way. In fact, non-ligand dependent ER signaling is well
characterized. The ligand dependent pathway of ER sig-
naling is initiated by steroid ligand binding to the ER. In
the non-ligand dependent pathway, activated kinase
growth factor receptors phosphorylate ER, leading to its
activation [33–36]. Loss of ERβ expression during tumor
progression was described in several other tumor entities
[6, 37, 38]. Seemingly, interplay between ERβ expression
and tissue specific distribution of growth factors may be
important for subsequent tumor progression.
In colon cancer cell lines, ERβ was shown to be the
predominant ER, whereas ERβ mRNA expression was a
lot lower and similar to normal tissue [6]. Similar results
Fig. 1 Nuclear expression of estrogen receptor beta (ERβ) in pancreatic ductal adenocarcinoma and corresponding normal tissue. Samples of
nontumorous pancreatic tissue (upper panel) and corresponding pancreatic ductal adenocarcinoma (lower panel) without (a and c) and with ERβ
expression (b and d) are shown. ERβ immunohistochemistry, magnification 640× (a-d)
Table 2 Correlation of estrogen receptor beta (ERβ) expression
with clinicopathological parameters
Variable n ERβ expression P value
Total 84 26 (31.0%)
Sex female 43 16 (37.2%) 0.243
male 41 10 (24.4%)
Age ≤60 years 24 7 (29.2%) 1.000
> 60 years 60 19 (31.7%)
T status 1–2 11 3 (27.3%) 1.000
3–4 73 23 (31.5%)
N status 0 35 11 (31.4%) 1.000
1 49 15 (30.6%)
Tumor grade 1–2 30 7 (23.3%) 0.328
3 54 19 (35.2%)
Residual tumora R0 39 11 (28.2%) 0.487
R1 42 15 (35.7%)
Perioperative
therapy
Surgery alone 30 13 (43.3%) 0.086
Chemoradiation/
Chemotherapy
54 13 (24.1%)
amissing information on resection status in three patients
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Fig. 2 Analysis of overall survival and disease free survival in 84 patients with resected pancreatic ductal adenocarcinoma
Table 3 Univariate analysis of prognostic factors for overall survival in resected pancreatic ductal adenocarcinoma
Variable Mean OS [months] 95% CI Median OS [months] p value
Total 27.0 22.3 – 31.6 21.4
Sex female 23.1 17.7 – 28.5 16.3 0.122
male 30.2 22.5 – 37.9 34.2
Age ≤60 years 29.4 21.6 – 37.1 21.4 0.398
> 60 years 25.4 20.1 – 30.8 20.2
T status T1–2 26.2 15.2 – 37.2 17.0 0.969
T3–4 26.8 21.8 – 31.9 22.2
N status N0 33.1 26.1 – 40.2 34.2 0.021
N1 21.5 16.1 – 26.8 16.3
Tumor grading G1–2 28.1 21.3 – 34.9 36.8 0.228
G3 25.3 19.6 – 31.0 16.7
Residual tumor R0 31.4 24.0 – 38.8 34.2 0.052
R1 19.8 15.7 – 23.9 16.7
ERβ expression negative 30.9 25.2 – 36.7 34.2 0.009
positive 16.6 12.7 – 20.4 12.2
Perioperative CRT/CTX 25.5 18.5 32.5 17.4 0.800
therapy none 27.2 21.5 32.9 21.4
CI confidence interval, OS overall survival, CRT chemoradiotherapy, CTX chemotherapy
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were obtained when examining ERβ expression in hu-
man tumor samples [37, 39].
No significant correlation was found between ERβ ex-
pression and clinicopathological features of patients and
PDAC specimens. A trend was seen towards a lower
ERβ expression in male patients, but statistical signifi-
cance was not reached. Circulating estrogen levels may
have some effect on ERβ expression. In fact, an upregu-
lation of ERβ by estrogen has been described previously
[40]. However, since the majority of the female patients
in our cohort is postmenopausal, as reflected by age dis-
tribution, this effect must be regarded as questionable.
Similarly, a trend was detected towards a higher expres-
sion of ERβ in less differentiated tumors, underlining a
role of ERβ in tumor progression towards a more ag-
gressive phenotype. This finding is supported by recent
data in breast cancer, where ERβ expression was found
to correlate with tumor grading and higher expression of
the proliferation marker Ki-67 in women with ERα nega-
tive breast cancer [9]. Similarly, in esophageal cancer, a
Table 4 Univariate analysis of prognostic factors for disease free survival in resected pancreatic ductal adenocarcinoma
Variable Mean DFS [months] 95% CI Median DFS [months] p value
Total 21.2 17.2 – 25.1 15.0
Sex female 20.4 15.2 – 25.6 12.2 0.485
male 22.0 16.1 – 27.9 16.3
Age ≤60 years 22.4 15.0 – 29.8 16.1 0.704
> 60 years 20.5 15.8 – 25.2 15.0
T status T1–2 25.6 13.5 – 37.7 16.3 0.701
T3–4 20.7 16.4 – 25.0 15.0
N status N0 25.1 18.9 – 31.2 20.0 0.066
N1 18.5 13.6 – 23.5 13.0
Tumor grading G1–2 24.4 17.3 – 31.6 20.1 0.293
G3 19.5 14.8 – 24.1 14.8
Residual tumor R0 25.9 19.4 – 32.5 21.5 0.018
R1 15.1 11.7 – 18.5 13.3
ERβ expression negative 23.5 18.7 – 28.4 16.3 0.037
positive 13.5 9.6 – 17.4 8.7
Perioperative CRT/CTX 21.4 16.5 – 26.3 15.0 0.800
therapy none 20.4 13.5 – 27.2 16.7
CI confidence interval, DFS disease free survival, CRT chemoradiotherapy, CTX chemotherapy
Fig. 3 Estrogen receptor beta (ERβ) expression in ductal pancreatic
adenocarcinoma. Percentages of ERβ expressing tumors are shown
by stratification into tumor dependent death after less than 12 and
more than 12 but less than 24 months, and overall survival more
than 24 months. Significantly fewer tumors of long-term overall
survivors expressed ERβ, compared to other strata (p = 0.043,
< 24 months versus 12–24 months; p = 0.0026, > 24 months versus
< 12 months; p = 0.000099, > 24 months versus < 24 months)
Table 5 Multivariate analysis of prognostic factors for overall
survival in pancreatic ductal adenocarcinoma
Parameter Hazard ratio 95% CI p value
ERβ expression 1.938 1.010–3.720 0.047
N1 1.831 0.954–3.517 0.069
Residual tumor 1.704 0.894–3.247 0.105
Male sex 0.628 0.355–1.311 0.251
CI confidence interval
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correlation of ERβ expression with poor differentiation
status and tumor stage was found in squamous cell car-
cinomas and in adenocarcinomas [41].
In the analyzed cohort, ERβ expression was found to
strongly correlate with a reduction of overall survival and
disease free survival in patients with resected pancreatic
adenocarcinoma in univariate and multivariate analyses.
Multivariate analysis of overall survival, revealed that the
expression of ERβ is an independent negative prognostic
factor. Patients with lymph node metastases had a shorter
survival, although this did not reach statistical significance.
Interestingly, resection status (R0 versus R1) also failed to
be a statistically significant prognostic factor of overall
survival and disease free survival in the multivariate ana-
lysis. This finding may be partially explained by underesti-
mation of the number of R1 resections [42], as
examination of circumferential resection margin was not
incorporated in routine pathological protocol when speci-
mens were analyzed originally.
At present, clinical data on the impact of ER expres-
sion on solid tumors on survival except in breast cancer
is not sufficient to establish a clear prognostic role of the
different ER subtypes. In esophageal squamous cell car-
cinoma and gastric adenocarcinoma, expression of ERα
in the absence of ERβ was described to correlate with an
adverse prognosis [38, 43]. In colorectal cancer, loss of
ERβ expression correlates with advanced cancer stages
and poor survival [44]. In hepatocellular cancer, both
ERα and ERβ are expressed [45]. Presence of a variant
ERα in hepatocellular carcinoma correlates with shorter
survival, compared to wild type ER [46].
However, some clinical and experimental data support
the hypothesis that ERβ expression may lead to a more
aggressive tumor phenotype. In ERα negative breast can-
cer, ERβ expression correlates with an increased Ki-67
expression, suggesting a higher proliferation rate within
the tumor cells. In the same cohort, ERβ expression
positively correlated with advanced tumor grade [9].
Similar findings were described in sarcoma patients [11].
In vitro proliferation of non small cell lung cancer cells
was reduced by siRNA mediated elimination of ERβ sig-
naling [10]. In contrast, ERβ deficiency results in an en-
hanced tumorigenesis in the small bowel, but not in the
colon of Apc (min/+) mice, suggesting a tumor suppres-
sor effect of ERβ [47].
The exact role of ER signaling in solid tumors remains
to be defined. Our data strongly suggest a tumor pro-
moting role of ERβ signaling in PDAC, which is in line
with previously published data on non small cell lung
cancer [21, 48]. However, there are studies showing an
effect of ERβ on tumor suppression, especially in colon
cancer [49–51]. These conflicting results may be ex-
plained by differences in the tissue distribution of the ER
subtypes and their splicing variants. Moreover, ER
signaling is embedded in a complex signaling network
controlling tumor cell growth and proliferation to the ef-
fect that context specific signaling interactions lead to
different effects in different tissue types [52]. In the
present study, the phosphorylation status of ERβ was
not examined. One can speculate that differences of tis-
sue specific ERβ phosphorylation lead to differential ER
mediated actions that are mediated by ligand independ-
ent ER signaling. Specifically, an extensive crosstalk be-
tween epidermal growth factor receptor (EGFR) and ER
mediated pathways is well documented in several tumor
types [40]. Since a strong EGFR expression is present in
PDAC, ER phosphorylation by EGFR mediated growth
signals and the resulting proliferative stimulus may be
an important contributor to the adverse prognostic ef-
fects observed. In fact, EGFR inhibition combined with
ER signaling disruption resulted in a marked inhibition
of tumor xenograft growth [10].
A limitation of the present study is the different periopera-
tive treatment of the patients included. In the cohort pre-
sented, 58% of the patients received perioperative
chemoradiation. Although a clear survival benefit of peri-
operative chemoradiation in patients with resectable PDAC
has not been shown [53], there is a possible impact of irradi-
ation and/or chemotherapy on ER expression [54]. However,
whether this is true for the ERβ subtype and is unknown,
and its clinical significance remains unclear. To clarify this
issue, additional studies may correlate the expression of ERβ
on pretherapeutic tumor biopsies with the expression on sur-
gical specimens after neoadjuvant therapy.
Conclusions
Here, the expression of ERβ was analyzed on surgical speci-
mens of patients with PDAC and correlated with overall
and disease free survival. ERβ was expressed on 31% of
PDAC surgical specimens. A correlation between ERβ ex-
pression and an adverse prognosis in resected PDAC seems
to exist. These data may be useful in defining a role of ERβ
expression as a prognostic indicator and as a potential mo-
lecular target in patients with advanced PDAC.
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